Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Avanir

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Funding boost for late-stage tau-based Alzheimer’s research

Singapore company TauRx receives $112m investment to take LMTX treatment into phase III

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links